Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
about
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementA prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients.Care for patients with severe mental illness: the general practitioner's role perspective.Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.Fatal diabetic ketoacidosis and antipsychotic medication.Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.A case series: evaluation of the metabolic safety of aripiprazoleCardiovascular effects of antipsychotics.Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.Metabolic syndrome in people with schizophrenia: a review.Association of metabolic syndrome with schizophreniaElevated prevalence of obesity, metabolic syndrome, and cardiovascular risk factors in bipolar disorderOlanzapine, weight change and metabolic effects: a naturalistic 12-month follow upMetabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study.Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Experimental drugs for bipolar psychosis.Impact of an Antipsychotic Discontinuation Bundle During Transitions of Care in Critically Ill Patients.A review of the nutritional challenges experienced by people living with severe mental illness: a role for dietitians in addressing physical health gaps.Royal Australian and New Zealand College of Psychiatrists expert consensus statement for the treatment, management and monitoring of the physical health of people with an enduring psychotic illness.Relationship Between Metabolic Syndrome and Clinical Features, and Its Personal-Social Performance in Patients with Schizophrenia.Factors influencing cardiometabolic monitoring practices in an adult community mental health service.Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder.A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone.
P2860
Q26783003-3B8C7A07-D62A-4BEB-82ED-72F56F3AEBC1Q33288884-DEAE709D-953E-4302-A403-B0EC7252F0E3Q33440011-15E921D6-0FDE-4E1E-8679-80E879571BFFQ34037969-A56C09F2-2260-46DF-9671-2D8F703666A5Q34646940-710C9322-9A05-490C-9633-8B8576C9A5B5Q35016170-1ACE52A3-E7D3-4A8D-B43A-21B36F52B00DQ36853249-23AC9BEE-D406-4B9D-9E37-EBA2B40C24C8Q36870063-E8ADB4A9-48C8-4BDA-BCA2-961BF2149044Q37102229-FA2F8A6F-5ACB-41FD-967D-D25B596F210DQ37129646-9597122D-A7DA-4B02-B18A-0AEE758100B9Q37201683-EAF7CADF-9BCD-4ED5-9FBB-6CB4AE71165CQ37218782-6142A933-EDEC-4B23-BFD1-F9AF81236173Q37494988-E7D2071F-0C1D-4098-9D52-3AA89AD32356Q37682840-B0604E2E-237E-4B2E-A79B-CAB660BBB6A7Q37865505-95A1CB01-4D20-4326-AA98-8E07EFD92604Q38995982-136D969D-1FC6-46C2-A96B-A852FB7C4F28Q39066117-553F5503-405F-4376-A5B4-C1FD5A21ECA5Q39248575-2C1EBDEB-4C98-464F-A6C3-A95CA4658DBCQ40273385-1B3B8BEA-31EB-4607-B600-B23B2FBEA2F8Q41587365-21EF7569-40DA-4D3A-956F-DB093BD5C772Q45771183-27E6367A-EA79-4C8D-9DFF-3E4572307518Q46756223-C275D781-30D8-4C3A-B81B-D3FCB5F8DED0Q47441084-2F2C029F-2542-4433-ABCA-390E698F0A99Q51391762-5D191202-2E5B-4521-A729-E6E1D133076C
P2860
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Metabolic abnormalities associ ...... for screening and monitoring.
@ast
Metabolic abnormalities associ ...... for screening and monitoring.
@en
type
label
Metabolic abnormalities associ ...... for screening and monitoring.
@ast
Metabolic abnormalities associ ...... for screening and monitoring.
@en
prefLabel
Metabolic abnormalities associ ...... for screening and monitoring.
@ast
Metabolic abnormalities associ ...... for screening and monitoring.
@en
P2093
P1476
Metabolic abnormalities associ ...... for screening and monitoring.
@en
P2093
Andre De Nayer
Dominique van Eyck
Marc De Hert
P356
10.1097/01.YIC.0000201496.23259.85
P478
21 Suppl 2
P577
2006-03-01T00:00:00Z